Sohonos

Sohonos · pharmadog

Patent cliff

source: FDA Orange Book

first barrier falls

Aug 16, 2028

~2.1 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (45)

Jun 8, 2037method-of-use (U-3676)US 10864194
Jun 8, 2037method-of-use (U-3676)US 10864194
Jun 8, 2037method-of-use (U-3676)US 10864194
Jun 8, 2037method-of-use (U-3676)US 10864194
Jun 8, 2037method-of-use (U-3676)US 10864194
Jun 8, 2037method-of-use (U-3676)US 11622959
Jun 8, 2037method-of-use (U-3676)US 11622959
Jun 8, 2037method-of-use (U-3676)US 11622959
Jun 8, 2037method-of-use (U-3676)US 11622959
Jun 8, 2037method-of-use (U-3676)US 11622959
Jun 8, 2037method-of-use (U-4031)US 12138245
Jun 8, 2037method-of-use (U-4031)US 12138245
Jun 8, 2037method-of-use (U-4031)US 12138245
Jun 8, 2037method-of-use (U-4031)US 12138245
Jun 8, 2037method-of-use (U-4031)US 12138245
Jun 8, 2037method-of-use (U-4031)US 12201614
Jun 8, 2037method-of-use (U-4031)US 12201614
Jun 8, 2037method-of-use (U-4031)US 12201614
Jun 8, 2037method-of-use (U-4031)US 12201614
Jun 8, 2037method-of-use (U-4031)US 12201614
Jun 8, 2037method-of-use (U-3676)US 12458626
Jun 8, 2037method-of-use (U-3676)US 12458626
Jun 8, 2037method-of-use (U-3676)US 12458626
Jun 8, 2037method-of-use (U-3676)US 12458626
Jun 8, 2037method-of-use (U-3676)US 12458626
Aug 31, 2031method-of-use (U-3676)US 10292954
Aug 31, 2031method-of-use (U-3676)US 10292954
Aug 31, 2031method-of-use (U-3676)US 10292954
Aug 31, 2031method-of-use (U-3676)US 10292954
Aug 31, 2031method-of-use (U-3676)US 10292954
Aug 31, 2031method-of-use (U-3966)US 12023312
Aug 31, 2031method-of-use (U-3966)US 12023312
Aug 31, 2031method-of-use (U-3966)US 12023312
Aug 31, 2031method-of-use (U-3966)US 12023312
Aug 31, 2031method-of-use (U-3966)US 12023312
Aug 31, 2031method-of-use (U-3676)US 9314439
Aug 31, 2031method-of-use (U-3676)US 9314439
Aug 31, 2031method-of-use (U-3676)US 9314439
Aug 31, 2031method-of-use (U-3676)US 9314439
Aug 31, 2031method-of-use (U-3676)US 9314439
Aug 31, 2031method-of-use (U-3676)US 9789074
Aug 31, 2031method-of-use (U-3676)US 9789074
Aug 31, 2031method-of-use (U-3676)US 9789074
Aug 31, 2031method-of-use (U-3676)US 9789074
Aug 31, 2031method-of-use (U-3676)US 9789074

FDA exclusivities (10)

Aug 16, 2030ODE-439Orphan Drug (7y)4.1y
Aug 16, 2030ODE-439Orphan Drug (7y)4.1y
Aug 16, 2030ODE-439Orphan Drug (7y)4.1y
Aug 16, 2030ODE-439Orphan Drug (7y)4.1y
Aug 16, 2030ODE-439Orphan Drug (7y)4.1y
Aug 16, 2028NCENew Chemical Entity (5y)2.1y

palovarotene

all catalysts(0)

News(0)

Patent cliff

patents (45)

FDA exclusivities (10)

Report a data issue

comments(0)

Trials studying palovarotene